REGENERON PHARMACEUTICALS, INC. Funds and ETFs Regeneron Pharmaceuticals, Inc.
Equities
REGN
US75886F1075
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 968 USD | +1.28% |
|
+3.24% | +10.21% |
ETFs positioned on Regeneron Pharmaceuticals, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.71% | 0 M€ | 0.00% | - | |
| 0.66% | 0 M€ | +7.68% | ||
| 0.47% | 330 M€ | -.--% | - | |
| 0.43% | 36 M€ | +22.19% | ||
| 0.42% | 219 M€ | +17.17% | - | |
| 0.42% | 1,448 M€ | -.--% | - | |
| 0.42% | 0 M€ | +12.62% | ||
| 0.38% | 1,174 M€ | +23.54% | ||
| 0.38% | 655 M€ | -.--% | - | |
| 0.38% | 273 M€ | -.--% | ||
| 0.35% | 1 M€ | +0.04% | ||
| 0.35% | 0 M€ | +18.09% | - | |
| 0.33% | 276 M€ | +11.40% | - | |
| 0.32% | 559 M€ | +14.30% | - | |
| 0.32% | 1,848 M€ | +18.39% | - | |
| 0.30% | 0 M€ | +18.44% | - | |
| 0.30% | 0 M€ | +8.05% | ||
| 0.30% | 0 M€ | +4.60% | - | |
| 0.29% | 1 M€ | -.--% | ||
| 0.28% | 0 M€ | +9.11% | ||
| 0.27% | 7 M€ | +0.11% | - | |
| 0.24% | 6 M€ | +17.98% | - | |
| 0.24% | 205 M€ | -.--% | ||
| 0.24% | 0 M€ | +9.11% | - | |
| 0.24% | 0 M€ | +6.76% | - | |
| 0.23% | 0 M€ | +3.88% | - | |
| 0.23% | 0 M€ | +6.12% | - |
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
955.8
USD
Average target price
1,034
USD
Spread / Average Target
+8.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.21% | 105B | |
| +2.97% | 108B | |
| +1.57% | 23.46B | |
| -12.77% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -6.50% | 17.19B | |
| +6.00% | 13.99B | |
| +37.20% | 12.53B | |
| +330.95% | 8.81B |
- Stock Market
- Equities
- REGN Stock
- Funds and ETFs Regeneron Pharmaceuticals, Inc.
